myelofibrosis | Cafepharma

Johnson & Johnson (JNJ) Strikes $935 Million Deal With Geron Corporation (GERN) To Co-Develop Imetelstat

Johnson & Johnson (JNJ) Strikes $935 Million Deal With Geron Corporation (GERN) To Co-Develop Imetelstat

Bidness Etc.

Incyte Building Blockbuster Drug One Disease At A Time

Incyte Building Blockbuster Drug One Disease At A Time

Investors.com

Geron Collaborates with J&J for Imetelstat

Geron Collaborates with J&J for Imetelstat

Yahoo/Zacks

acute myelogenous leukemia

myelodysplastic syndrome

Geron sells last drug in pipeline to J&J unit

Geron sells last drug in pipeline to J&J unit

Yahoo/Reuters

After A Long Year, An Update on Geron's Myelofibrosis Drug Is Disclosed

After A Long Year, An Update on Geron's Myelofibrosis Drug Is Disclosed

TheStreet.com

FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

Yahoo

Geron Set To Explode As FDA Releases Partial Clinical Hold On Imetelstat Myelofibrosis Trial

Geron Set To Explode As FDA Releases Partial Clinical Hold On Imetelstat Myelofibrosis Trial

Seeking Alpha

Geron And The Mayo Clinic Working In Parallel To Release Clinical Hold Of Imetelstat

Geron And The Mayo Clinic Working In Parallel To Release Clinical Hold Of Imetelstat

Seeking Alpha

Geron says FDA halts patient enrollment in another cancer trial

Geron says FDA halts patient enrollment in another cancer trial

Yahoo/Reuters

Clinical Trial Hold Of Geron's Revolutionary Drug Imetelstat Will Be Temporary

Clinical Trial Hold Of Geron's Revolutionary Drug Imetelstat Will Be Temporary

Seeking Alpha

clinical trials

Geron Plummets as FDA Halts Development of Blood Disorder Drug

Geron Plummets as FDA Halts Development of Blood Disorder Drug

Bloomberg

Geron Shares React to Imetelstat Mayo Study Update

Geron Shares React to Imetelstat Mayo Study Update

TheStreet.com

Keep an Eye on Geron, Novartis, Cell Therapeutics, and Verastem Today

Keep an Eye on Geron, Novartis, Cell Therapeutics, and Verastem Today

Motley Fool

Cell Therapeutics

Geron Soars After Study Shows Bone Marrow Drug’s Benefit

Geron Soars After Study Shows Bone Marrow Drug’s Benefit

Bloomberg

Whither Sanofi R&D? Another Setback For An Oncology Drug

Whither Sanofi R&D? Another Setback For An Oncology Drug

Pharmalot

Baxter, Cell Therapeutics announce collaboration to develop pacritinib

Baxter, Cell Therapeutics announce collaboration to develop pacritinib

Yahoo/Fly on the Wall

Baxter International

Cell Therapeutics

JAK2/FLT3 inhibitors

Geron soars after myelofibrosis drug shows 44% response rate

Geron soars after myelofibrosis drug shows 44% response rate

The Fly on the Wall

Incyte Has First-Mover Advantage

Incyte Has First-Mover Advantage

Motley Fool

Myelofibrosis Battle: Novartis Vs. Sanofi

Myelofibrosis Battle: Novartis Vs. Sanofi

Seeking Alpha

This Biotech Has So Many Reasons to Be Liked

This Biotech Has So Many Reasons to Be Liked

Motley Fool

Click here to subscribe to daily news headlines in your email inbox